Centene Corporation issued the following announcement on Jan. 30.
Centene Corporation (NYSE: CNC) announced that it has completed its acquisition of PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and treating rare diseases.
"We are pleased to welcome the PANTHERx team to the Centene family," said Michael F. Neidorff, Chairman, President and Chief Executive Officer for Centene. "PANTHERx is a leader in rare disease pharmacy and brings a unique capability to our comprehensive pharmacy portfolio. Together, we will ensure patients living with complex and rare diseases get the quality care they deserve."
As previously announced, PANTHERx and its management team will continue to operate independently as part of Centene's Envolve Pharmacy Solutions, a total drug management program that includes integrated Pharmacy Benefit Manager (PBM) services and specialty pharmacy solutions to millions of members throughout the United States.
Original source can be found here.
Alerts Sign-up